Dr Lal Pathlabs

BSE: 539524 01 Dec 2025

Healthcare

₹ 3055.95 ▲ 0.09%

Dr. Lal Pathlabs Limited specializes in Healthcare Service Provider within the Healthcare sector.

Dr Lal Pathlabs

BSE: 539524 01 Dec 2025

Healthcare

₹ 3055.95 ▲ 0.09%

Dr. Lal Pathlabs Limited specializes in Healthcare Service Provider within the Healthcare sector.

High

3065

Low

3055

Open

3055

Prev Close

3053.2

Market Cap

25642.85 Cr

Dr Lal Pathlabs - Share Price & Details

Market Cap

₹ 25,642.85

WAP

3,033.21

Turnover

1.30(Cr.)

TTQ

4312

2 Week Avg Qty

0.10(Lakh)

Circuit Limit

4,312.00/2,442.60

Stock P/E

52.2

Book Value

₹260.0

Dividend Yield

0.75

ROCE

28.9

ROE / PB

25.93 / 12.36

Face Value

10.00

PEG Ratio

4.25

EVEBITDA

₹31.9

Debt

157

CMP / FCF

57.1

Debt to equity

₹0.07

NP Ann

492

High price all time

4,246

Piotroski score

₹8.0

Graham Number

599.0

No. Eq. Shares

8.38

Net CF

₹-68.3

Net profit

518

Price to book value

12.3

Interest Coverage

₹32.2

Low price all time

696.0

Industry PE

38.6

Reserves

₹2,089

Free Cash Flow

₹516

Broker Recommendations

Date	Author	Type	Reco Price	Target Price	Potential	Source	PDF Link
20 Jul 2025	Emkay Global Financial Services	Buy	₹3,000.75	₹3,100	3.1%	moneycontrol	View
26 Apr 2025	Emkay Global Financial Services	Buy	₹2,906.55	₹3,100	10.2%	moneycontrol	View
26 Apr 2025	ICICI Securities	Hold	₹2,906.55	₹2,900	4.3%	moneycontrol	View
30 Jan 2025	Emkay Global Financial Services	Buy	₹2,879.4	₹3,250	13.5%	moneycontrol	View
24 Oct 2024	ICICI Securities	Hold	₹3,053.5	₹3,100	3.7%	moneycontrol	View
08 Aug 2024	ICICI Securities	Hold	₹3,194.75	₹3,240	8.4%	moneycontrol	View
10 May 2024	Emkay Global Financial Services	Buy	₹2,348.85	₹2,800	-5.8%	moneycontrol	View

Price Chart

Volume Chart

Peer Comparison

Stock	Total Income	Net Profit	Net Sales	EPS	Market Cap (in Cr)	P/E
FABINO ENTERPRISES LIMITED	NA	NA	NA	NA	5.09	84.8
Triochem Products Ltd.,	2.95	-1.93	NA	-7.86	0
Dr. Lal Pathlabs Limited	7224.0	1457.0	6996.0	17.43	26,762	52.2
J.B.CHEMICALS & PHARMACEUTICAL	11,002.40	2,078.20	10,849.00	13.08	26153	38.2
PIRAMAL PHARMA LIMITED	21,093.20	-992.20	20,437.20	-0.75	24954	289.0

Peer Comparison Chart

About Dr Lal Pathlabs

Dr. Lal Pathlabs Limited, with Security Code 539524, is a leading player in the Healthcare Service Provider industry, categorized under the Healthcare sector, offering Equity instruments.

Order Book

Latest News

Dr Lal PathLabs Ltd (DLPL IN): Here’s Why Growth to Accelerate and Margin to Improve

(20 Sep 2025)

Dr Lal PathLabs sees strong start to FY26 with double-digit growth driven by volume expansion resulting from expanding geographic presence.

Daily Brief Health Care: Vivani Medical, Medcaptain Medical Technology, Dr Lal PathLabs Ltd, Immix Biopharma Inc, MDxHealth SA, Oncology Institute and more

(20 Sep 2025)

Vivani Medical has set Oct 8, 2025 as teh record date for its earlier announced spin-off of its neuromodulation subsidiary, Cortigent Inc.

Dr. Lal PathLabs Limited's (NSE:LALPATHLAB): Top Key Executive Arvind Lal is the most bullish insider, and their stock value gained 3.2% last week

(16 Sep 2025)

Key Insights Dr. Lal PathLabs' significant insider ownership suggests inherent interests in company's expansion A total...

From Partition to Pandemic, How Dr Lal PathLabs Built an Indian Diagnostics Empire

(30 Aug 2025)

Dr Lal PathLabs, founded by Dr SK Lal in 1949, has grown into one of India's largest diagnostics chains. With a legacy of accuracy and trust...

Dr. Lal PathLabs to Hold Analyst/Institutional Investor Meetings in September 2025

(26 Aug 2025)

Dr. Lal PathLabs has announced that it will be holding meetings with analysts and institutional investors in September 2025.

Dr. Lal PathLabs pioneers AI integration in cancer diagnosis in India

(25 Aug 2025)

In a pioneering move set to transform cancer diagnostics in India, Dr. Lal PathLabs (DLPL) has become the first laboratory in the country to...

Quarterly Table

Standalone Consolidated

Metrics	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
Sales	476.0	479.0	534.5	583.9	528.1	577.2	640.7	699.6
Expenses	345.9	348.7	379.0	399.4	382.7	418.1	457.3	484.5
Operating Profit	130.1	130.3	155.5	184.5	145.4	159.1	183.4	215.1
OPM %	27.33%	27.2%	29.09%	31.6%	27.53%	27.56%	28.62%	30.75%
Other Income	15.1	15.9	28.8	22.0	29.5	25.2	26.3	22.8
Interest	6.5	5.9	5.5	5.0	4.8	4.8	4.5	4.6
Depreciation	19.2	19.8	17.8	18.2	18.9	34.6	32.8	38.5
Profit before tax	119.5	120.5	161.0	183.3	151.2	144.9	172.4	194.8
Tax %	-26.1%	-25.7%	-23.7%	-26.2%	24.3%	2.4%	25%	25.2%
Net Profit	88.3	89.5	122.9	135.2	114.5	148.4	129.3	145.7
EPS in Rs	10.75	10.71	14.73	16.2	13.71	0	15.49	17.43

Metrics	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Sep 2025
Sales	601.3	538.9	545.4	601.9	660.2	596.7	602.6	730.6
Expenses	423.5	398.3	400.7	431.9	457.7	442.7	433.6	506.5
Operating Profit	177.8	140.6	144.7	170.0	202.5	154.0	169.0	224.1
OPM %	29.57%	26.09%	26.53%	28.24%	30.67%	25.81%	28.05%	30.67%
Other Income	18.1	18.3	18.4	20.6	21.9	25.1	25.8	24.8
Interest	7.8	7.0	6.6	6.0	6.0	5.3	5.0	4.8
Depreciation	35.9	36.0	36.6	34.7	35.3	35.5	36.4	40.5
Profit before tax	152.2	115.9	119.9	149.9	183.1	138.3	153.4	203.6
Tax %	-27.3%	-29.1%	-28.4%	28.1%	28.6%	-29.1%	1.4%	-25.2%
Net Profit	110.7	82.2	85.8	107.8	130.8	98.1	155.5	152.2
EPS in Rs	13.12	9.76	10.12	12.76	15.48	11.58	0	0

Shareholding Distribution

Shareholding Pattern

Compounded Data

Consolidated

Standalone

Compounded Sales Growth
10 Years:	14%
5 Years:	13%
3 Years:	8%
TTM:	20%

Compounded Profit Growth
10 Years:	18%
5 Years:	17%
3 Years:	13%
TTM:	29%

Stock Price CAGR
10 Years:	0%
5 Years:	14%
3 Years:	13%
1 Year:	10%

Compounded Sales Growth
10 Years:	14%
5 Years:	13%
3 Years:	6%
TTM:	11%

Compounded Profit Growth
10 Years:	18%
5 Years:	17%
3 Years:	12%
TTM:	36%

Stock Price CAGR
10 Years:	0%
5 Years:	14%
3 Years:	13%
1 Year:	10%

All Deals

Date	Stock	Party	Deal	Acq. Mode	Trans.	Quan.	Price	Value

Stock Mutual Funds Data

Order Book

News Date ▲▼	Headline ▲▼	Issuer Entity ▲▼	Issuer Type ▲▼	Order Size ▲▼	Time Period ▲▼
Loading company updates…

Loading technicals…

Moving Averages

Latest Close: — • Records Used: — • Last Trading Date: —

Simple Moving Averages (SMA)

Period	SMA Value	Status

Exponential Moving Averages (EMA)

Period	EMA Value	Status

Oscillators

Key Oscillators

latest calculation

Indicator	Value

Dr Lal Pathlabs

Dr Lal Pathlabs

Dr Lal Pathlabs - Share Price & Details

Broker Recommendations

Price Chart

Volume Chart

Peer Comparison

Peer Comparison Chart

About Dr Lal Pathlabs

Order Book

Latest News

Dr Lal PathLabs Ltd (DLPL IN): Here’s Why Growth to Accelerate and Margin to Improve

Daily Brief Health Care: Vivani Medical, Medcaptain Medical Technology, Dr Lal PathLabs Ltd, Immix Biopharma Inc, MDxHealth SA, Oncology Institute and more

Dr. Lal PathLabs Limited's (NSE:LALPATHLAB): Top Key Executive Arvind Lal is the most bullish insider, and their stock value gained 3.2% last week

From Partition to Pandemic, How Dr Lal PathLabs Built an Indian Diagnostics Empire

Dr. Lal PathLabs to Hold Analyst/Institutional Investor Meetings in September 2025

Dr. Lal PathLabs pioneers AI integration in cancer diagnosis in India

Dr. Lal Path Labs rises 3% on adopting new AI cancer diagnostic tool

Technical Analysis: Dr. Lal PathLabs Limited (LALPATHLAB) - Proven strategies for superior portfolio growth

Dr. Lal PathLabs Limited Just Beat EPS By 12%: Here's What Analysts Think Will Happen Next

Coal India, Dr Lal PathLabs, Ramco Cements, Blue Dart to turn ex-dividend on Wednesday

Dr Lal PathLabs Banks On Volume Growth To Achieve 11-12% Revenue Growth In FY26

Dr. Lal PathLabs Q1FY26 Profit Up 24%; ₹6 Dividend Declared

Dr. Lal PathLabs Limited (LALPATHLAB) Expands into New Market - Consistently exceptional gains

Dr Lal PathLabs Q1 results: Profit up 24% aided by higher sampling; interim dividend declared

Dr. Lal PathLabs Limited (539524) vs yyy - Free Real-Time Stock Data

Bullish Pattern Emerging on Dr. Lal PathLabs Limited (539524) - Free Trading Psychology Coaching

Dr. Lal PathLabs Limited (LALPATHLAB) Signs Major Deal - Free Stock Market Forecast Reports

Buy Dr Lal Pathlabs; target of Rs 3100: Emkay

Bullish Pattern Emerging on Dr. Lal PathLabs Limited (539524) - Superior trading gains

Dr Lal Pathlabs declares board meeting date to announce Q1 results 2025, dividend

Dr. Lal PathLabs Limited (539524) Quarterly Results Are Out - Rapid capital growth

Dr. Lal PathLabs adds Illumina’s NovaSeq X Series to expand genomics capabilities

Dr. Lal PathLabs Strengthens Its Genomics Capabilities With Illumina’s NovaSeq X Series.

Dr. Lal PathLabs strengthens genomics capabilities with Illumina’s NovaSeq X Series

Dr. Lal PathLabs Integrates NovaSeq X Series in Genomics; Time to Go Long?

Dr Lal PathLabs adds Illumina’s NovaSeq X to its genomics division

Unnecessary emergency hospitalisation due to erroneous lab report: Dr Lal Pathlabs slapped Rs 3.5 lakh...

Dr. Lal Pathlabs Faces Market Sentiment Shift Amid Strong Financial Performance

Delhi consumer panel upholds verdict indicting Dr Lal Pathlabs for wrong report

Dr Lal PathLabs, Metropolis, other diagnostic stocks fall up to 3% after Amazon launches home testing serv

Metropolis, Dr Lal PathLabs shares dip up to 3% as Amazon enters diagnostic market

Here's why diagnostics stocks Metropolis, Dr. Lal are declining on Monday

Dr. Lal Pathlabs Faces Mixed Technical Signals Amid Market Evaluation Shift

Dr Lal PathLabs report in spotlight after leaked test reveals Olympic boxer Imane Khelif has male chromos

Is Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

Dr. Lal Pathlabs Shows Signs Of Rebound After Long Downtrend: SEBI RA Harshit Goel

Dr. Lal Pathlabs Shows Signs Of Rebound After Long Downtrend: SEBI RA Harshit Goel By Stocktwits

Dr Lal Pathlabs Shows Strong Performance Amid Sector Gains and Market Dynamics

Q4 Results Highlights: Shriram Finance profit up 9.95%, NII at Rs 5,565.5 cr; Maruti Suzuki profit drops by 1.04%

Dr Lal PathLabs feels margin heat as it chases growth, long-term outlook remains strong | Stock Market News

Dr Lal PathLabs Targets 27% Margin In FY26, Plans To Foray Into New Regions

Dr Lal Path Labs Q4 Results: Co beats quarterly profit view on medical testing boom

Dr Lal Path Labs Q4FY25 results: Net profit rises 83.2% to ₹155 crore

Dr Lal Pathlabs Faces Potential Trend Reversal Amid Broader Market Resilience

Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) Business Is Trailing The Market But Its Shares Aren't

Dr Lal PathLabs’ shares slip over 4% as margins likely to see pressure on expansion plans

Dr. Lal PathLabs first to launch advanced test for amyloidosis

Dr. Lal PathLabs Q4 Results: Profit Rises 83%, Beats Estimates

Dr Lal PathLabs Q4 results beat estimates, declares ₹6 final dividend

Dr. Lal Path Labs posts Q4 FY25 consolidated PAT at Rs. 154.8 Cr

Dr Lal PathLabs Reports 81.4% Profit Jump in Q4 Result

Dr. Lal PathLabs becomes South Asia's first to launch advanced test for amyloidosis

Dr. Lal PathLabs becomes south Asia’s first diagnostic chain to offer advance test for amyloidosis: a rare, life-threatening protein disorder

Dr. Lal PathLabs liquidates Suburban Diagnostics to streamline operations

JM Financial upgrades Dr Lal Pathlabs to Buy, target price Rs 3,600

Dr Lal PathLabs reports higher Q3 profit on steady testing demand; dividend declared

India's Dr Lal Path Labs posts higher Q3 profit on steady testing demand

Investor Optimism Abounds Dr. Lal PathLabs Limited (NSE:LALPATHLAB) But Growth Is Lacking

Stocks To Buy Today: ONGC, Dr. Lal Path Labs, Titan, And More

Antara partners with Dr. Lal PathLabs to strengthen its geriatric care services

Dr Lal Pathlabs data leak: Legal opinions on liabilities, punishments, penalty the diagnostic chain might face

Antara Senior Care, Dr. Lal PathLabs collaborate to bolster healthcare

Pioneers in Senior Care Antara Partners with Leading Diagnostics Player Dr. Lal PathLabs to Strengthen its Geriatric Care Services

Pioneers in Senior Care, Antara, Partners with Leading Diagnostics Player Dr. Lal PathLabs to Strengthen its Geriatric Care Services

Don't Ignore The Insider Selling In Dr. Lal PathLabs

Dr. Lal PathLabs (NSE:LALPATHLAB) jumps 6.5% this week, though earnings growth is still tracking behind five-year shareholder returns

Dr Lal Pathlabs Stock Sees 3.25% Increase, Outperforms Sector and Sensex

Dr Lal PathLab Standalone September 2024 Net Sales at Rs 583.90 crore, up 9.82% Y-o-Y

Colgate, Bharat Forge and 3 more: Axis Direct recommends buying these stocks for 2 weeks; check targets, st...